Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reprogramming Tumor-Associated Neutrophils to Enhance Radio-Immunotherapy.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

Bacteria-Derived Nanobody-Decorated Nanoplatform Restores T Cell Immunity Post-Radiotherapy.

ACS nano·2026
Same author

Engineered <i>Escherichia coli Nissle</i> 1917 targeted delivery of extracellular PD-L1-mFc fragment for treating inflammatory bowel disease.

Acta pharmaceutica Sinica. B·2025
Same author

NK Cell-Derived Small Extracellular Vesicles Armed With CLDN4-Targeting Peptides Potentiate Radiotherapy in Gastric Cancer.

Journal of extracellular vesicles·2025
Same author

MOF-Based Nanoplatform Enables Synergistic Hypoxia-Activated Chemotherapy and Chemodynamic Therapy for Colon Cancer.

ACS applied materials & interfaces·2025
Same author

pH-Responsive Probiotic-Liposome Hybrid System Synergistically Treats Radiation-Induced Injury via Dual Mechanisms of Anti-Inflammatory and Microbiome Modulation.

Advanced healthcare materials·2025
Same journal

Correction to "Nanoparticles (NPs)-Meditated LncRNA AFAP1-AS1 Silencing to Block Wnt/β-Catenin Signaling Pathway for Synergistic Reversal of Radioresistance and Effective Cancer Radiotherapy".

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same journal

Femtosecond-Laser Nanocavitation Regenerates SERS-Active Plasmonic Nanogaps for Longitudinal Molecular Sensing at Biointerfaces.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same journal

Correction to "Bioinspired Polyacrylic Acid-Based Dressing: Wet Adhesive, Self-Healing, and Multi-Biofunctional Coacervate Hydrogel Accelerates Wound Healing".

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same journal

Non-Line-of-Sight Passive Ammonia Sensor Loaded With MXene/In<sub>2</sub>O<sub>3</sub> Composites for Agricultural Products Quality Deterioration Detection.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same journal

Cerium Nanoparticle-Mediated Inhibition of the NSUN2/m<sup>5</sup>C Axis Suppresses Synovial Aggression in Rheumatoid Arthritis.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same journal

Biomimetic Nanoplatform for Dual Target Nano-Metabolic Therapy in Diabetes-Associated Biofilm Infections.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Bioluminescent Bacterial Imaging In Vivo
05:06

Bioluminescent Bacterial Imaging In Vivo

Published on: November 4, 2012

15.8K

Engineered Bacteria-Vesicle Delivered Lactate Reprogramming Boosts Tumor Radiosensitivity.

Fei Peng1, Zhe Lei1, Zhehao Zhang1

  • 1Department of Pathology, State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinary Sciences (RAD-X), the First Affiliated Hospital, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Cancer Institute, Suzhou Medical College, Soochow University, Suzhou, Jiangsu, China.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|January 4, 2026
PubMed
Summary
This summary is machine-generated.

Engineered bacteria (ENHL) deplete tumor lactate, overcoming cancer radioresistance. This precision microbial therapy enhances radiotherapy efficacy by neutralizing acidic stress and improving immune response.

Keywords:
engineered bacterialactate reprogrammingradioresistancetargeted deliverytumor microenvironment

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.4K
Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
07:56

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

13.9K

Related Experiment Videos

Last Updated: Jan 7, 2026

Bioluminescent Bacterial Imaging In Vivo
05:06

Bioluminescent Bacterial Imaging In Vivo

Published on: November 4, 2012

15.8K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.4K
Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
07:56

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

13.9K

Area of Science:

  • Microbiology
  • Oncology
  • Biotechnology

Background:

  • Radiotherapy (RT) is a key cancer treatment, but tumor radioresistance limits its effectiveness.
  • Lactate accumulation in the tumor microenvironment (TME) drives radioresistance by affecting DNA repair, immune suppression, and metabolism.
  • Targeting lactate offers a strategy to overcome therapeutic resistance in cancer.

Purpose of the Study:

  • To develop a precision microbial therapy using engineered bacteria to target and deplete lactate in the TME.
  • To evaluate the efficacy of engineered bacteria (ENHL) and their derived lactate oxidase (LOx)-loaded outer membrane vesicles (OMVs) in radiosensitizing colorectal cancer.
  • To assess the in vivo tumor colonization, lactate neutralization, and therapeutic effects of ENHL.

Main Methods:

  • Engineered Escherichia coli Nissle 1917 (EcNΔnlpIIHCL, ENHL) with enhanced OMV biogenesis and a bifunctional surface display system were created.
  • Engineered bacteria were designed to deliver lactate oxidase (LOx) for lactate neutralization.
  • In vitro and in vivo studies utilized colorectal cancer models to assess ENHL's efficacy in radiosensitization, tumor targeting, and immune modulation.

Main Results:

  • ENHL and LOx-loaded OMVs effectively reduced lactate levels in the TME.
  • Treatment with ENHL significantly enhanced the radiosensitivity of colorectal cancer cells.
  • Oral administration of ENHL led to selective tumor colonization, arabinose-inducible LOx expression, improved radiosensitivity, and increased immune cell infiltration.

Conclusions:

  • Precision microbial therapy with ENHL offers a novel strategy to overcome radioresistance in colorectal cancer by targeting tumor lactate.
  • The engineered bacteria effectively deliver lactate-neutralizing enzymes to the TME, improving therapeutic outcomes.
  • This approach holds promise for clinical translation to enhance cancer treatment efficacy.